CSI Market
Sign In | Register

Takeda Pharmaceutical Limited (TAK) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TAK Annual Cash Flow →
From Takeda Pharmaceutical Limited through Mar 31 2024, changes in Mar 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
12 Months 		0 0 0 (Mar 31 2024)
Operating Activities
Income688.86
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Decrease Increase In Inventories-
Adjustments For Increase Decrease In Trade And Other Payables-
Changes In Other Provisions-
Impairment Loss-
Expense From Equitysettled Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets-
Gains Losses On Subsequent Increase In Fair Value Less Costs To Sell Not In Excess Of Recognised Cumulative Impairment Loss-
Gains Losses On Disposals Of Property Plant And Equipment-
Gain Loss On Disposal Of Business-
Income Taxes Paid Classified As Operating Activities-
Increase Decrease In Contingent Consideration Asset Liability-
Adjustments For Finance Income Cost-
Income taxes0.00
Losses/ -gains on Investments net-911.27
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities13,882.26
Discontinued operations0.00
Net Cash flow from Operating Activities14,426.34
Investing Activities
Capital Expenditures-1,279.04
Sale of Capital Items0.50
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Dividends Received Classified As Investing Activities4.04
Proceeds From Withdrawal Of Restricted Deposits-
Other Inflows Outflows Of Cash Classified As Investing Activities-
Proceeds From Sales Of Interests In Associates-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash FlowsFrom Losing Control Of Subsidiaries OrOther Businesses Classified As Investing Activities130.94
Purchase Of InterestsIn Associates-6.40
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-1,548.58
Discontinued operations0.00
Net Cash Flow from Investing Activities-2,338.13
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-2,859.61
Payments To Noncontrolling Interests-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid-1,926.87
Net Cash Flow from Financing Activities-4,786.48
Effect of exchange rate on cash flow-390.49
Discontinued operations0.00
Free Cash Flow13,147.80
Total Cash Flow2,916.13
4 historic quarters locked

Sign in to unlock the full Takeda Pharmaceutical Limited cash flow history.

Sign In Create Free Account

About Takeda Pharmaceutical Co Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20260331)
  • Filed with the SEC: June 17, 2026
  • Source: tak-20260331.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001395064-26-000177

Figures are derived from filed reports and may be restated. Historical data is subject to revision.